Circle Pharma, a spinout of UCSF and UC Santa Cruz, has collected series B funding from investors including another UC campus, Berkeley.

Humanised antibody-based drug developer Harbour BioMed has now raised $210m altogether following a series B-plus round featuring Zhejiang University Future Capital.

Biotalys, a bio-fungicide and pesticide developer based on VIB technology previously known as AgroSavfe, has added $11m to its series C round.

Keio Innovation Initative has backed a $74.4m round for the polymer-based battery producer, which is advancing research from Keio's professor Hideaki Horie.

Inventec Appliances Corp has contributed to a round that will enable USF-founded Molekule to further develop and scale its air purification technology.

Tarana, a broadband services provider advancing research from UC Berkeley, has raised $24m in funding with commitments for an additional $36m.

University of Oxford-founded OMass Therapeutics has extended its series A round to progress a pipeline targeting immunological and genetic disorders.

Sonoma Biotherapeutics has emerged from stealth with $40m to develop regulatory T-cell therapies for autoimmune and degenerative diseases.

Verily has taken part in an oversubscribed series B round that will fund the UC Berkeley spinout's expansion from diagnostics to gene editing and drug development.

The inflammatory disease therapy developer emerged from stealth to commercialise research from several Max Planck institutes and LDC.